Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial (2018)
- Authors:
- USP affiliated authors: YASUNAKA, JENICER KAZUMI UMADA YOKOYAMA - ICB ; ULIANA, SILVIA RENI BORTOLIN - ICB
- Unidade: ICB
- DOI: 10.1111/tmi.13119
- Subjects: PARASITOLOGIA; LEISHMANIOSE CUTÂNEA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: West Sussex
- Date published: 2018
- Source:
- Título do periódico: Tropical Medicine & International Health
- ISSN: 1365-3156
- Volume/Número/Paginação/Ano: v. 23, n. 9, p. 936-942, 2018
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: bronze
-
ABNT
MACHADO, Paulo R. L. et al. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Tropical Medicine & International Health, v. 23, n. 9, p. 936-942, 2018Tradução . . Disponível em: https://doi.org/10.1111/tmi.13119. Acesso em: 23 abr. 2024. -
APA
Machado, P. R. L., Ribeiro, C. S., França‐Costa, J., Dourado, M. E. F., Trinconi, C. T., Yokoyama‐Yasunaka, J. K. U., et al. (2018). Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. Tropical Medicine & International Health, 23( 9), 936-942. doi:10.1111/tmi.13119 -
NLM
Machado PRL, Ribeiro CS, França‐Costa J, Dourado MEF, Trinconi CT, Yokoyama‐Yasunaka JKU, Malta‐Santos H, Borges VM, Carvalho EM, Uliana SRB. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial [Internet]. Tropical Medicine & International Health. 2018 ; 23( 9): 936-942.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1111/tmi.13119 -
Vancouver
Machado PRL, Ribeiro CS, França‐Costa J, Dourado MEF, Trinconi CT, Yokoyama‐Yasunaka JKU, Malta‐Santos H, Borges VM, Carvalho EM, Uliana SRB. Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial [Internet]. Tropical Medicine & International Health. 2018 ; 23( 9): 936-942.[citado 2024 abr. 23 ] Available from: https://doi.org/10.1111/tmi.13119 - Discovery of synthetic Leishmania Inhibitors by screening of a 2-arylbenzothiophene library
- Parasite burden in Leishmania (Leishmania) amazonensis-infected mice: validation of luciferase as a quantitative tool
- Susceptibility to miltefosine in brazilian clinical isolates of Leishmania (Viannia) braziliensis
- Antileishmanial activity of the estrogen receptor modulator raloxifene
- The anticancer drug tamoxifen is active against Trypanosoma cruzi in vitro but ineffective in the treatment of the acute phase of Chagas disease in mice
- A dysflagellar mutant of Leishmania (Viannia) braziliensis isolated from a cutaneous leishmaniasis patient
- Combination therapy with Tamoxifen and Amphotericin B in experimental cutaneous Leishmaniasis
- In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B
- Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma
- Leishmania is not prone to develop resistance to tamoxifen
Informações sobre o DOI: 10.1111/tmi.13119 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
